BeBetter Med Inc. (SHA:688759)

Market Cap	9.76B
Revenue (ttm)	n/a
Net Income	-177.50M
EPS	-0.41
Shares Out	450.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,303,085
Open	21.53
Previous Close	21.57
Day's Range	21.41 - 22.49
52-Week Range	19.98 - 57.47
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About BeBetter Med

BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases. It offers BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; developing BEBT-209, a CDK4/6 selective inhibitor for metastatic triple-negative breast cancer; and BEBT-109, a selective EGFR inhibitor designed for NSCLC. The company also develops BEBT-503, an oral, well-balanced pan-PPAR for metabolic diseases including diabetes and mash;...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 177
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688759

Financial Performance

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Oct 8, 2026

Data Sources Report a data error